Literature DB >> 28411042

Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030.

Gregory J Dore1, Jason Grebely2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28411042     DOI: 10.1016/j.jhep.2017.03.035

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  5 in total

1.  The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.

Authors:  Andrew M Hill; Sanjay Nath; Bryony Simmons
Journal:  J Virus Erad       Date:  2017-07-01

Review 2.  Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.

Authors:  Sophia E Schröeder; Alisa Pedrana; Nick Scott; David Wilson; Christian Kuschel; Lisa Aufegger; Rifat Atun; Ricardo Baptista-Leite; Maia Butsashvili; Manal El-Sayed; Aneley Getahun; Saeed Hamid; Radi Hammad; Ellen 't Hoen; Sharon J Hutchinson; Jeffrey V Lazarus; Olufunmilayo Lesi; Wangsheng Li; Rosmawati Binti Mohamed; Sigurdur Olafsson; Raquel Peck; Annette H Sohn; Mark Sonderup; Catherine W Spearman; Tracy Swan; Mark Thursz; Tim Walker; Margaret Hellard; Jessica Howell
Journal:  Liver Int       Date:  2019-09-04       Impact factor: 5.828

3.  Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.

Authors:  Jisoo A Kwon; Georgina M Chambers; Fabio Luciani; Lei Zhang; Shamin Kinathil; Dennis Kim; Hla-Hla Thein; Willings Botha; Sandra Thompson; Andrew Lloyd; Lorraine Yap; Richard T Gray; Tony Butler
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

4.  Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.

Authors:  Aaron G Lim; Nick Scott; Josephine G Walker; Saeed Hamid; Margaret Hellard; Peter Vickerman
Journal:  PLoS Med       Date:  2021-10-19       Impact factor: 11.069

5.  Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.

Authors:  Katherine Heath
Journal:  Clinicoecon Outcomes Res       Date:  2018-09-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.